Canaccord analyst Whitney Ijem lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $11 from $34 and keeps a Buy rating on the shares. The firm noted last week’s announcement of a clinical hold on lead program RP-A501 for Danon Disease following AEs (adverse event), a protocol adjustment, new AEs and ultimately a patient death. This is a clear setback from a timing and sentiment perspective.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts
- Rocket Pharmaceuticals downgraded at Evercore following patient death in study
- Rocket Pharmaceuticals downgraded to In Line from Outperform at Evercore ISI
- Rocket Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
- Rocket Pharmaceuticals price target lowered to $19 from $51 at Scotiabank
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue